Publication: 3780

Publication: 3780

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Nat Commun vol 14

Year:: 2023
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: Alliance-data-source,-external-user
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:

Parents:: 3618
Children:: None

Program:: TRP
Primary Committee:: Correl Sci NOS
Sec. Committees:

Pharmas:: Novartis
Grants:: U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233337, UG1CA233373

Corr. Author:
Authors:: Mattia Rediti Aranzazu Fernandez-Martinez David Venet Françoise Rothé Katherine A. Hoadley Joel S. Parker Baljit Singh Jordan D. Campbell Karla V. Ballman David W. Hillman Eric P. Winer Sarra El-Abed Martine Piccart Serena Di Cosimo William Fraser Symmans Ian E. Krop Roberto Salgado Sherene Loi Lajos Pusztai Charles M. Perou Lisa A. Carey Christos Sotiriou

Networks:: LAPS-CT018, LAPS-NC007, LAPS-TX035

Study: Alliance-A152117
Multiple Studies, or Legacy Studies in Alliance Study:: CALGB-40601
Phases:: N/A, 3

Keywords:: Prognostic markers, Breast cancer, Tumour immunology